Clinical Trials Browser

Phase 1/2 × Interventional × Interleukin-2 × Clear all

NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1/2 Terminated

5 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06158828 2026-05-05

ABCD-NK

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT06961357 2026-03-31

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Phase 1/2 Completed

Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05357027 2026-01-21

HPV16 E6 TCR T Cells for Cervical Carcinoma

Phase 1/2 Terminated

Uterine Cervical Neoplasms

NCT05307874 2025-12-24

EVICTION-2

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT07255664 2025-12-08

ProbeTILity

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase 1/2 Terminated

8 enrolled 12 charts

GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05086692 2025-07-09

ABILITY-1

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06532799 2024-11-12

BAH250

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06532812 2024-11-12

BAH249

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06530303 2024-11-05

BAH248

Phase 1/2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06640582 2024-11-05

BAH2472

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT06538012 2024-10-15

BAH2472

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

Neoplasm Metastasis, Recurrence

NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT01898793 2024-01-17

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Terminated

89 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04729543 2023-12-04

MC2TCR

Phase 1/2 Recruiting

DermatologicHead & Neck

Uveal Melanoma, Head and Neck Neoplasms, Melanoma

NCT05981001 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Ovarian Neoplasms

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Phase 1/2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

Melanoma

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

Melanoma

NCT00924326 2022-01-12

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

Phase 1/2 Completed

43 enrolled 19 charts

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02989714 2021-07-13

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Phase 1/2 Completed

13 enrolled 11 charts

Carcinoma, Renal Cell

NCT04389229 2020-12-16

OVSTAR

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

NCT03778619 2020-07-28

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

NCT01701479 2020-07-14

LTI

Phase 1/2 Unknown

Neuroblastoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

13 enrolled 12 charts

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT01550367 2020-01-02

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Phase 1/2 Completed

30 enrolled 20 charts

Carcinoma, Renal Cell

NCT03111901 2019-07-12

UVA-AM-002

Phase 1/2 Withdrawn

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT01191034 2019-03-12

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Phase 1/2 Terminated

Melanoma

NCT02173093 2019-01-29

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Phase 1/2 Unknown

Neuroblastoma

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma